Member Info for EarlyBird-Rns

Did you read my last post? Hurry....

She's Rising!

Check out my last post;)

16 June 2014 Strategic Natural Resources Plc ("SNR" or the "Company") Dismissal of London Commodity Brokers' winding up petition Further to the announcements by the Company on 25 April 2014, 12 May 2014, 13 May 2014 and 6 June 2014, the board of SNR, the AIM quoted natural resources developer operating in South Africa, which indirectly owns 74% of Elitheni Coal (Pty) Limited, announces that the winding up petition filed with the Companies Court in London by London Commodity Brokers ("LCB") has today been dismissed, with the consent of LCB and SNR, following SNR's settlement of the agreed amounts due from SNR to LCB, details of which were announced on 13 May 2014 and 6 June 2014. For further information, please contact: Strategic Natural Resources plc Alex MacDonald, CEO and Chairman +44 (0)20 3328 5656 --------------------- Allenby Capital Limited -

Yingbin Ian He, Non-Executive Chairman of Vatukoula Gold Mines, commented: "As previously advised this quarter's production remained at a restricted rate, as we continue work to secure long - term financing. We have maintained our policy of carrying out only essential development required for current production requirements and limited long-term development when possible. We have begun discussions with some strategic investors to fund the additional US$ 20 million as highlighted in the general meeting notice." Underground Production and Development Mining operations at Vatukoula continue to be limited by capital and cash flow constraints. We have prioritised our mining operations on production stoping followed by essential development. The program to open new areas has been maintained, but on a limited basis. Ore production can be maintained in the short term, but development to open new areas must be initiated before our long term production targets can be achieved. Total tonnes of ore and waste mined for the third quarter ended May 2013 decreased to 85,893 tonnes compared to 94,793 tonnes in the same period last year. The lower tonnages were primarily driven by decreases in operating and capital development metres. The ore delivered from underground for the third quarter was 76, 950 tonnes compared to 100,182 tonnes in the same period last year. This reduction was due to lower stope availability, lower average stope heights and lower strike drive development which is typically delivered as ore. The average underground grade for the period was 4.85 grams per tonne, which was higher than the same period last year (4.53 grams per tonne). The year on year variance is a result of some higher grades (6.27 grams per tonne) delivered from the Philip Shaft. The cash costs have increased from US$ 1,812 per ounce of gold and US$ 157 per tonne of ore in the 3 months period ending May 2013 to US$ 1,938 per ounce and US$ 196 per tonne for the 3 months ended May 2014. These increases in costs are primarily driven by lower tonnages and lower grades processed. Surface Production Production for the 3 months ended May 2014 from surface oxides and sulphide waste piles was 24,921 tonnes at a grade of 2.50 grams per tonne (40,424 tonne at 2.36 grams per tonne for the same period last year). Ore was delivered from both sulphide waste dumps and surface oxide production. Sulphide waste is being processed through the sulphide circuit. Vatukoula Treatment Plant ("VTP") During the 3 months ended May 2014, the VTP processed 76,950 tonnes compared with 100,182 for the same period last year. The decrease was driven by lower underground and surface ore delivered to the mill. The average grade increased to 4.06 grams per tonne from 3.48 grams per tonne delivered over the same period. This was driven by higher grade ore from underground mining operations and lower tonnages mined from surface. Gold recovery was 80.89% fo

13 June 2014 Vatukoula Gold Mines plc ("Vatukoula" or "the Company") Operational Update for the three months ended 31(st) May 2013 Vatukoula Gold Mines Plc (AIM:VGM), the AIM listed gold producer, is pleased to announce its operational results from its 100% owned Vatukoula Gold Mine in Fiji for the third quarter ended 31(st) May 2013. 3 months 3 months 3 months 3 months 3 months ended ended ended ended ended May 2014 Feb 2014 Nov 2013 Aug 2013 May 2013 Operating Results (Q3) (Q2) (Q1) (Q4) (Q3) ----------------------------------------- ---------- ---------- ---------- ---------- ---------- Underground Mining Total underground tonnes mined (ore, waste & capital) 85,893 106,437 104,805 96,701 94,793 Operating development (metres) 2,746 2,876 2,822 3,199 3,666 Strike drive development (metres) 448 449 379 395 405 Capital development (metres) 1,040 1,535 1,327 1,131 976 Total development (metres) 4,234 4,860 4,528 4,725 5,047 Sulphide Plant Sulphide ore delivered (tonnes) 53,079 54,027 62,073 54,637 59,456 Sulphide head grade (grams/tonne) 4.85 5.05 5.30 5.85 4.53 Oxide Plant Oxide ore delivered (tonnes) 24,921 10,993 47,593 57,076 40,424 Oxide head grade (grams/tonne) 2.50 2.05 2.06 2.15 2.36 Total (sulphide + oxide) Ore processed (tonnes) 76,950 66,895 107,115 111,936 100,182 Average ore head grade (grams/tonne) 4.06 4.54 3.97 3.96 3.48 Total recovery 80.89% 80.76% 79.37% 79.44% 79.76% Gold produced (ounces) 8,139 7,622 11,090 11,442 9,005 Gold shipped (ounces) 7,794 7,700 11,415 11,219 8,704 ----------------------------------------- ---------- ---------- ---------- ---------- ---------- Cash Costs ----------------------------------------- ---------- ---------- ---------- ---------- ---------- Cash cost per ounce shipped (US$) 1,938 1,618 1,360 1,393 1,812 Cash cost per tonne mined and milled (US$/tonne) 196 186 145 140 157 Average realised gold price (US$/ounce) 1,271

She's moving upwards again...

Again...

The potential earning numbers for SNG are astounding! Once she settles down and if the SP drops back to somewhere reasonable next week... I'll probably take a mid-long position...

Cheers for that:)

She's now dropping and I probably will take another go if I can get a reasonable entry... Oh ya... I completely agreed with you yesterday on LEG... Simply I was hoping to play a little volatility with a quick trade...

I tried looking for you pre-market once I read the Rns.... Perhaps next time...

A quick swing trade:)

Was my 3k buy:)

Nobody has picked-up on the Rns! AZN could play SNG up to 5x times more than their market cap...

At Open... She's going to really move!

Under the terms of the exclusive licence agreement, AstraZeneca will pay Synairgen a $7.25 million up-front fee and potential development, regulatory and commercial milestones of up to $225 million. In addition, AstraZeneca will pay tiered royalties ranging from single-digit up to mid-teens on commercial sales. AstraZeneca will be responsible for future development costs.

12 June 2014 Synairgen plc ("Synairgen" or the "Company") ASTRAZENECA IN-LICENSES SYNAIRGEN'S SNG001 AS A NOVEL IMMUNO-MODULATORY THERAPY FOR VIRAL-INDUCED EXACERBATIONS IN ASTHMA Phase IIa clinical study to commence in patients with severe asthma Southampton, UK: Synairgen plc (LSE: SNG) today announced a global licence agreement with AstraZeneca for SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating respiratory tract viral infections in patients with severe asthma. SNG001 supports the immune system by correcting a deficiency which makes patients vulnerable to respiratory tract viral infections. Under the terms of the exclusive licence agreement, AstraZeneca will pay Synairgen a $7.25 million up-front fee and potential development, regulatory and commercial milestones of up to $225 million. In addition, AstraZeneca will pay tiered royalties ranging from single-digit up to mid-teens on commercial sales. AstraZeneca will be responsible for future development costs. In early 2015, AstraZeneca will commence a Phase IIa study in patients with severe asthma, building on available clinical data from an initial Phase lla trial in a broad asthma population. SNG001 also provides the opportunity to expand the clinical programme in other pulmonary diseases including chronic obstructive pulmonary disease (COPD). Maarten Kraan, Head of Respiratory, Inflammation & Autoimmune Innovative Medicines, AstraZeneca, said: "Respiratory disease is a core therapeutic area for AstraZeneca, and a key growth platform for the company. Our approach includes addressing associated complications that patients experience, as well as developing treatments for the underlying disease. SNG001 is an innovative and targeted therapy that has, if successful, the potential to offer a step-change in the treatment of severe asthma, and possibly COPD." Richard Marsden, Synairgen CEO, commented: "We're delighted that this truly innovative programme, discovered at the University of Southampton and developed by Synairgen, will be taken forward by AstraZeneca. With its strong research focus and extensive experience in respiratory disease, AstraZeneca's commitment to developing novel medicines for patients with asthma and COPD makes them the ideal partner for SNG001." Simon Shaw, Chairman of Synairgen, said: "We are very pleased to have progressed SNG001 through pre-clinical and clinical development to the stage where it could attract such a well-qualified global development partner to progress the programme. We now look forward to using our platform technology, extensively used to develop IFN-beta, to assess and, where appropriate, in-license new therapeutic opportunities for progression to the clinic." -ENDS- For further information, please contact: Synairgen plc Tel: + 44 (0) Richard Marsden, Chief Executive 23 8051 2800

The buy is dropping...

Getting a 5.77 buy now... Needs a bit more of attention before I give it a go....